Combination therapy of an inhaled corticosteroid and a bronchodilator is a frontline treatment for asthma and chronic obstructive pulmonary disease (COPD).  PDE4i has been recognized as an approved approach to managing COPD.  We will present data for GS-9759 a novel bifunctional compound that has both PDE4i and �2-agonist activity in a single molecule.  Data will illustrate the advantages of PDE4i and LABA combination therapy.

Dual β<sub>2</sub>-adrenoceptor agonists-PDE4 inhibitors for the treatment of respiratory disease:  (III) Discovery of GS-9759

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.

Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of respiratory disease: (III) Discovery of GS-9759

Dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of respiratory disease: (III) Discovery of GS-9759